Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 11 studies | 51% ± 25% | |
| oligodendrocyte precursor cell | 10 studies | 30% ± 11% | |
| GABAergic neuron | 9 studies | 46% ± 26% | |
| astrocyte | 8 studies | 27% ± 10% | |
| oligodendrocyte | 8 studies | 25% ± 9% | |
| endothelial cell | 7 studies | 31% ± 13% | |
| interneuron | 6 studies | 53% ± 25% | |
| neuron | 5 studies | 41% ± 15% | |
| macrophage | 5 studies | 23% ± 7% | |
| epithelial cell | 5 studies | 25% ± 6% | |
| granule cell | 4 studies | 32% ± 11% | |
| GABAergic interneuron | 3 studies | 39% ± 5% | |
| microglial cell | 3 studies | 21% ± 5% | |
| ciliated cell | 3 studies | 22% ± 3% | |
| type I pneumocyte | 3 studies | 21% ± 6% | |
| transit amplifying cell | 3 studies | 28% ± 10% | |
| plasmacytoid dendritic cell | 3 studies | 24% ± 9% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 15 studies | 36% ± 22% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 3969.89 | 458 / 459 | 100% | 31.00 | 1113 / 1118 |
| prostate | 100% | 4119.88 | 244 / 245 | 100% | 21.89 | 500 / 502 |
| intestine | 100% | 3161.27 | 964 / 966 | 99% | 21.53 | 523 / 527 |
| bladder | 100% | 1913.24 | 21 / 21 | 99% | 19.53 | 498 / 504 |
| pancreas | 100% | 2678.13 | 328 / 328 | 98% | 15.88 | 175 / 178 |
| lung | 99% | 2791.13 | 570 / 578 | 100% | 24.25 | 1150 / 1155 |
| thymus | 100% | 4439.90 | 653 / 653 | 98% | 14.88 | 593 / 605 |
| stomach | 100% | 2826.62 | 359 / 359 | 98% | 20.32 | 280 / 286 |
| uterus | 99% | 2487.79 | 169 / 170 | 98% | 20.98 | 452 / 459 |
| esophagus | 98% | 2195.70 | 1413 / 1445 | 100% | 27.75 | 183 / 183 |
| brain | 98% | 5110.01 | 2576 / 2642 | 98% | 16.26 | 694 / 705 |
| skin | 100% | 3599.67 | 1809 / 1809 | 95% | 20.25 | 448 / 472 |
| ovary | 94% | 1910.80 | 170 / 180 | 98% | 16.95 | 423 / 430 |
| kidney | 100% | 2373.11 | 89 / 89 | 92% | 10.97 | 828 / 901 |
| adrenal gland | 99% | 2206.06 | 256 / 258 | 79% | 11.06 | 181 / 230 |
| liver | 84% | 1011.66 | 190 / 226 | 88% | 13.00 | 359 / 406 |
| spleen | 100% | 4521.99 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 16.23 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 11.54 | 1 / 1 |
| adipose | 100% | 2654.04 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 98% | 2034.71 | 787 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 16.13 | 28 / 29 |
| eye | 0% | 0 | 0 / 0 | 91% | 15.55 | 73 / 80 |
| heart | 89% | 1400.67 | 770 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 80% | 1179.67 | 1068 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 41% | 2016.82 | 380 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0030488 | Biological process | tRNA methylation |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0005634 | Cellular component | nucleus |
| GO_0003723 | Molecular function | RNA binding |
| GO_0016423 | Molecular function | tRNA (guanine) methyltransferase activity |
| Gene name | TARBP1 |
| Protein name | Probable methyltransferase TARBP1 (EC 2.1.1.-) (TAR RNA-binding protein 1) (TAR RNA-binding protein of 185 kDa) (TRP-185) |
| Synonyms | TRM3 TRP185 |
| Description | FUNCTION: Probable S-adenosyl-L-methionine-dependent methyltransferase which methylates RNA molecules such as tRNAs. .; FUNCTION: (Microbial infection) In case of infection by HIV-1, it binds to the loop region of TAR RNA, a region also bound by RNA polymerase II . Binding of TARBP1 and RNA polymerase II to HIV-1 TAR RNA is mutually exclusive, suggesting that TARBP1 may function alone or in conjunction with HIV-1 Tat to disengage RNA polymerase II from HIV-1 TAR RNA . . |
| Accessions | Q13395 ENST00000040877.2 |